AMGEN, INC. for AMGEN INC
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to drug pricing Issues related to Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.3345, PBM Price Transparency and Accountability Act H.R. 6166, Lowering Drug Costs for American Families Act S.3019 - No Big Blockbuster Bailouts Act H.Res. 928 - Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| RUTH HOFFMAN | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE | — |
| MATTHEW MCMURRAY | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| CHAD PETTIT | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
| CHASE THOMAS | — |
Health Issues HCR
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act HR 5526 Biosimilar Red Tape Elimination Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 5509 Safe Step act HR 5256 340B Access Act HR 4581 340B Patients Act S2296 NDAA FY2026 National Defense Authorization Act, issued related to Biosecure Act H.R. 6703 Lower Health Care Premiums for All Americans Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act H.Res. 928 Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| RUTH HOFFMAN | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE | — |
| MATTHEW MCMURRAY | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| CHAD PETTIT | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
| CHASE THOMAS | — |
Taxation/Internal Revenue Code TAX
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to patents and taxes
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| JORDAN LYNN LAYSON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
| CHASE THOMAS | — |
Copyright/Patent/Trademark CPT
Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to patent thickets/product hopping Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling Issues related to patents and taxes S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S.2296-- NDAA (FY 2026 National Defense Authorization Act-- BIOSECURE language) S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) HR 6485 Skinny Labels Big Saving Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM O'BRIEN | — |
| HELEN RHEE | — |
Tariff (miscellaneous tariff bills) TAR
Issues related to tariffs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE | — |
| MATTHEW MCMURRAY | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
| CHASE THOMAS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.